Veramyst (fluticasone furoate nasal spray) / GSK - LARVOL DELTA

Effect of Individualised Homeopathic Medicine as Adjunct to Fluticasone Furoate for Allergic Rhinitis: A Prospective, Randomised, Open-Label, Controlled Trial. (PubMed, Homeopathy) - "No serious adverse events were reported.Adding an IHM to SOC did not enhance clinical outcomes during the 12-week treatment but significantly better symptoms control and quality of life at 18 weeks, suggesting a sustained benefit for AR relapse. These findings support IHMs as potential adjunct for long-term AR management, warranting further investigation."

Journal • Allergic Rhinitis • Conjunctivitis • Immunology • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology

Diagnosis and management of allergic rhinitis: An Indian expert consensus by otorhinolaryngologists. (PubMed, Asia Pac Allergy) - "Another critical consensus was on the use of the fixed-dose combination of fluticasone furoate and oxymetazoline hydrochloride nasal spray for the persistent and moderate-severe blocker phenotype of AR. This expert consensus will help physicians in their clinical practice and complement effective diagnosis and management of AR."

Journal • Review • Allergic Rhinitis • Immunology • Inflammation • Otorhinolaryngology

As Needed Versus Regular Intranasal Corticosteroid in Children With Perennial Allergic Rhinitis (clinicaltrials.gov) - P3 | N=68 | Completed | Sponsor: Mahidol University | Recruiting ➔ Completed | Phase classification: PN/A ➔ P3

Phase classification • Trial completion • Allergic Rhinitis • Immunology • Inflammation

A Novel Metered Dose Inhaler Formulation of Triple-Drug Fixed-Dose Combination of Vilanterol, Glycopyrronium, and Fluticasone Furoate: A Phase III, Randomized, Multicenter Trial to Evaluate the Efficacy and Safety in Indian Patients With Uncontrolled Asthma. (PubMed, Clin Ther) - "Efficacy and safety of VIL-GLY-FF-MDI were found to be similar to those of IND-GLY-MF-DPI in Indian patients with persistent asthma. Clinical Trial Registry India identifier: CTRI/2024/01/061230."

Journal • P3 data • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

A pragmatic, multicentre, placebo-controlled, 3-arm, double-blinded, randomised controlled trial, incorporating an internal pilot, to determine the role of bronchodilators in preventing exacerbations of bronchiectasis (WBC 2024) - "Interventions 12 months one puff daily of either dual therapy (55 micrograms umeclidinium [LAMA] and 22 micrograms vilanterol [LABA]), triple therapy (as per dual therapy plus 92 micrograms fluticasone furoate [ICS]) or matched placebo dry powder inhalers, randomised in a 2:2:1 ratio respectively... COVID-19 impacted delivery of the trial effecting staff capacity, set-up timelines and ultimately recruitment to the pilot. The trial is unable to provide evidence on the superiority or cost-effectiveness of LABA/LAMA or ICS/LABA/LAMA to placebo at reducing mean exacerbation rates over 12 months or the non-inferiority of LABA/LAMA to ICS/LABA/LAMA. However, the results do suggest there is a signal of efficacy and that a larger trial may be able to provide evidence."

Clinical • Asthma • Bronchiectasis • Chronic Obstructive Pulmonary Disease • Immunology • Infectious Disease • Inflammation • Novel Coronavirus Disease • Pulmonary Disease • Respiratory Diseases

Cost-effectiveness analysis of corticosteroid nasal sprays for allergic rhinitis in Japan. (PubMed, Asian Pac J Allergy Immunol) - "Fluticasone propionate is the most cost-effective agent. As it was not often prescribed in the fiscal year 2020, physicians should understand our results to sustain the reduction of healthcare expenditures."

HEOR • Journal • Allergic Rhinitis • Immunology • Inflammation

Comparison of Allergic Rhinitis Treatments on Patient Satisfaction: A MASK-air and EAACI Methodological Committee Report. (PubMed, Allergy) - "Using patient-reported data, we evaluated different medication classes and treatments in terms of satisfaction and co-medication frequency. These results provide key insights into the acceptability of AR treatments and will contribute to future treatment guidelines."

Journal • Allergic Rhinitis • Immunology • Inflammation

Impact of inhaled triple therapy on symptomatic tobacco-exposed individuals with normal spirometry (ERS 2025) - " In this investigator-initiated, interventional trial, symptomatic tobacco-exposed individuals with ≥10pack- year smoking history and FEV1/FVC>0.7 (intervention group) underwent evaluation, including quality-of-life assessments, lung function, computed tomography, and exercise capacity measurements at baseline and after 12 weeks of therapy with ICS(Fluticasone furoate 92mcg), LABA(Vilanterol 22mcg) and LAMA(Umeclidinium 55mcg). Inhaled triple therapy significantly reduces the burden of small airway disease and alleviates symptoms in symptomatic tobacco-exposed individuals with preserved FEV1/FVC ratio."

Clinical • Respiratory Diseases

Efficacy and safety of novel fixed dose combination of vilanterol, glycopyrronium, and fluticasone furoate dry powder inhaler: A phase 3, randomized, non-inferiority trial compared with fixed dose combination of indacaterol, glycopyrronium, and mometasone furoate dry powder inhaler in Indian asthma patients. (PubMed, Respir Med) - "VIL-GLY-FF DPI was found non-inferior to IND-GLY-MF DPI in improving trough FEV1 response. The test FDC was well-tolerated in Indian patients with persistent asthma."

Head-to-Head • Journal • P3 data • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Assessment of drug permeability using a small airway microphysiological system. (PubMed, Front Pharmacol) - "Insignificant nonspecific binding to the MPS was observed with albuterol sulfate, formoterol fumarate, and olodaterol hydrochloride (HCl), while fluticasone furoate showed significant nonspecific binding as only 6%-44% of the drug was recovered at 30 and 120 min, respectively. Taken together, the small airway MPS recapitulated relevant cell types and many morphological features in the lung. The apparent permeabilities measured indicated that albuterol sulfate and formoterol fumarate would be categorized as highly permeable, while olodaterol HCl would be categorized as a low permeable drug."

Journal

Pharmacovigilance of drug-induced cataract using the FDA Adverse Event Reporting System. (PubMed, Sci Rep) - "Disproportionality analysis identified 24 drugs significantly associated with cataract risk, with the highest risks linked to glucocorticoids (e.g., fluticasone furoate, triamcinolone), insulin analogs (e.g., insulin glargine, insulin human), and other agents like nitisinone and ranibizumab. Difluprednate showed the strongest association (Bayesian Confidence Propagation Neural Network [BCPNN] = 7.83), followed by prednisolone (BCPNN = 6.84) and erdafitinib (BCPNN = 5.44)...The majority of cases were reported in females (57.9%), with a noticeable annual increase in cases. This study provides a comprehensive pharmacovigilance evaluation, offering insights into high-risk medications, their onset patterns, and demographic trends, contributing to improved clinical decision-making and cataract prevention strategies."

Adverse events • Journal • Cataract • Oncology • Ophthalmology

Assessment of leukotriene E4 as a long term marker of inflammation between regular maintenance (36 weeks therapy) versus as-needed intranasal corticosteroid use in pediatric allergic rhinitis (EAACI 2025) - "We gave them intranasal corticosteroid (fluticasone furoate) for 36 weeks treatment...Conclusion Daily use of intranasal corticosteroid is more important and effective in treatment of pediatric AR. LTE4 in EBC assessment may be useful in the evaluation of inflammation of pediatric AR."

Clinical • Allergic Rhinitis • Immunology • Inflammation

Impact of Simultaneous Step-Up to High-Dose Fluticasone Furoate and Addition of Umeclidinium on a Clinical Remission Endpoint in Asthma: CAPTAIN Post Hoc Analysis (ATS 2025) - P3 | "This abstract is funded by: GSK (205715/NCT02924688) Rationale: Clinical remission (CR) is an ambitious and achievable treatment goal in asthma. Both increasing FF dose and adding UMEC contributed to improving clinical outcomes in patients with asthma. These results suggest that the greater odds of meeting the CR endpoint with FF/UMEC/VI 200/62.5/25 versus FF/VI 100/25 were mostly driven by the addition of UMEC. Although data over 52 weeks are needed to confirm achievement of CR, patients not yet considered for biologics with moderate-to-severe asthma uncontrolled on FF/VI 100/25 may gain greater benefits with simultaneous step-up to high-dose triple therapy versus increasing FF dose or adding UMEC alone."

Clinical • Retrospective data • Asthma • Immunology • Respiratory Diseases

Evaluation of Patient-Reported Outcomes (PRO) and Satisfaction With Once-daily Vilanterol/Fluticasone Furoate (VI/FF) in Uncontrolled Asthma Patients Experiencing Frequent Exacerbations on Conventional Treatment: Sub Group Analysis of a Real World Study (ATS 2025) - "Patients with uncontrolled asthma experiencing frequent exacerbations on conventional therapy showed high adherence to treatment when switched to VI/FF. This adherence was linked to increased patient satisfaction & significant improvement in asthma symptoms, indicating VI/FF a promising option for this group."

Clinical • Patient reported outcomes • Real-world • Real-world evidence • Asthma • Cough • Immunology • Pain • Respiratory Diseases

Impact of inhaled corticosteroids on metabolic dysfunction-associated steatotic liver disease risk in COPD patients. (PubMed, Respir Med Res) - "In COPD patients, long-term use of ICS may be associated with an increased risk of developing MASLD. Further studies are needed to explore strategies to mitigate the potential risk of MASLD in COPD patients requiring ICS therapy."

Journal • Chronic Obstructive Pulmonary Disease • Hepatology • Immunology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Pulmonary Disease • Respiratory Diseases

Extrafine formulation of beclomethasone dipropionate/formoterol fumarate/glycopyrronium bromide delivered via pressurized metered-dose inhaler in the treatment of asthma: a review. (PubMed, Ther Adv Respir Dis) - "One such formulation is the extrafine combination of beclomethasone dipropionate (BDP), fluticasone furoate (FF), and glycopyrronium bromide (GB), which is delivered via a single pressurized metered-dose inhaler (pMDI). The cost-effectiveness analysis of the BDP/FF/GB SITT suggests favorable outcomes compared to traditional ICS/LABA and ICS/LABA plus tiotropium combinations. Additional data will be forthcoming from the ongoing real-life TRIMAXIMIZE observational study."

Journal • Review • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

U-LABA/ICS Effects on Exercise Performance, Vilanterol (clinicaltrials.gov) - P=N/A | N=30 | Recruiting | Sponsor: Morten Hostrup, PhD | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Sep 2025 ➔ Jul 2026

Trial completion date • Trial primary completion date

Role of Lung Function for Exercise Capacity in Well-trained Individuals (clinicaltrials.gov) - P=N/A | N=60 | Recruiting | Sponsor: Morten Hostrup, PhD | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Sep 2025 ➔ Jul 2026

Trial completion date • Trial primary completion date • Inflammation • Respiratory Diseases

Treatment of allergic rhinitis and allergic conjunctivitis. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Allergic Rhinitis • Allergy • Conjunctivitis • Immunology • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology

Real-life effectiveness of once-daily single-inhaler triple therapy (FF-UMEC-VI) after switching from dual therapy (ICS-LABA) in patients with symptomatic asthma: trelegy ellipta for real asthma control study. (PubMed, Front Allergy) - "A well-designed, protocol-driven randomized controlled trial (RCT) has demonstrated the efficacy of fluticasone furoate-umeclidinium-vilanterol (FF-UMEC-VI) in patients with asthma, but there is a lack of real-world data that can be used to translate the results of the RCT into clinical practice. Cough VAS also significantly decreased but did not reach a minimal clinically important difference. In patients with symptomatic asthma showing insufficient control, an improvement in the asthma symptoms was observed after switching to FF-UMEC-VI at the equivalent corticosteroid dose, accompanied by an improvement in FEV1."

Journal • Asthma • Cough • Immunology • Pulmonary Disease • Respiratory Diseases

Comparison table: Some nasal sprays for seasonal allergic rhinitis. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Allergic Rhinitis • Allergy • Immunology • Inflammation

Allergen Immunotherapy in Autoimmune Terrain: A Case Study. (PubMed, Indian J Otolaryngol Head Neck Surg) - "The patient had been on AIT for six months and was using intranasal fluticasone furoate nasal spray daily...However, a risk-benefit analysis favored the continuation of AIT along with the initiation of L-thyroxine therapy...The continuation of AIT was justified by its benefits in managing allergic rhinitis and the manageable nature of hypothyroidism with hormone therapy. This case highlights the importance of personalized medicine and continuous monitoring in treatment decisions for patients with coexisting conditions."

Journal • Allergic Rhinitis • Allergy • Asthma • Atopic Dermatitis • Conjunctivitis • Dermatitis • Dermatology • Endocrine Disorders • Fatigue • Food Hypersensitivity • Immunology • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology • Pulmonary Disease • Respiratory Diseases

MicroED Structures of Fluticasone Furoate and Fluticasone Propionate Provide New Insights into Their Function. (PubMed, Cryst Growth Des) - "This study underscores the combined use of MicroED and DFT calculations to provide a comprehensive understanding of conformational and energy changes during drug administration. The quantitative comparison also highlights the subtle structural differences that may lead to significant changes in the pharmaceutical properties."

Journal • Allergic Rhinitis • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases

A Brief Report on a Systematic Review of Real-World Effectiveness Studies of ICS/LAMA/LABA for Treatment of Adults with Asthma in the US. (PubMed, Pulm Ther) - "This brief communication reports a systematic review that identified few sources of SITT or MITT in US patients with asthma. Although inclusion of observational studies can result in reporting/selection bias, we identified greater clinical benefits with triple therapies versus dual therapies."

Journal • Real-world evidence • Review • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Fluticasone Propionate/Azelastine versus Fluticasone Furoate for Treating Moderate-to-Severe Persistent Non-Allergic Rhinitis from Thai Adult Chronic Rhinitis Prospective Cohort (TARhiC) (AAAAI-WAO 2025) - "Adverse events were comparable between the two groups, except for a more frequent bitter taste reported from the FP/Aze group. Conclusions Both FP/Aze and FF similarly improved nasal symptoms and quality of life in patients with moderate-to-severe persistent NAR ."

Clinical • Allergic Rhinitis • Conjunctivitis • Immunology • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology